Deans' stroke musings: Roche stops dalcetrapib trial for lack of benefit

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, May 7, 2012

Roche stops dalcetrapib trial for lack of benefit - HDL cholesterol

HDL-cholesterol-boosting drug stopped testing.
http://www.theheart.org/article/1395141.do
Roche has stopped the phase 3 dal-OUTCOMES trial of the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib after interim analysis of the study showed the HDL-cholesterol-boosting drug was not significantly reducing cardiovascular adverse events [1].

As reported by heartwire, the earlier dal-PLAQUE study showed that dalcetrapib reduced inflammation in the carotid artery and that there was an inverse relationship between HDL-cholesterol levels and markers of arterial inflammation in patients treated with the drug. Dal-OUTCOMES was a major morbidity and mortality study currently planned for about 16 000 stable coronary heart disease patients with recent acute coronary syndrome (ACS). Patients in the study were randomized to either 600 mg daily of dalcetrapib and standard medical therapy or placebo and standard medical therapy.

The primary outcome was time to first occurrence of any component of the composite cardiovascular events. Secondary outcomes included all-cause mortality, change from baseline in blood lipids and lipoprotein levels, adverse events, lab parameters, vital signs, and ECG. The company says there were no adverse safety signals in the interim analysis.

Researchers hoped dalcetrapib was a CETP inhibitor that could succeed where torcetrapib failed. Torcetrapib was abandoned when studies showed it appeared to increase the risk of cardiovascular events despite substantially increasing HDL-cholesterol levels.